Category: Healthcare Industry

“Superspreaders” identified as driving cause of 2014 Ebola epidemic

A new study has shown that in the catastrophic 2014-2015 Ebola epidemic in West Africa, about three percent of the people infected were responsible for infecting 61 percent of all cases. The issue of so-called “superspreaders,” according to researchers who published their findings in Proceedings of the National Academy of Sciences, is so significant that it’s important to put a better face on just who these people are and then better reach them with public health measures designed to control the spread of infectious disease during epidemics.

ViiV Healthcare announces detailed positive phase III results for…

In the SWORD studies, the two-drug regimen showed comparable efficacy to three- or four-drug regimensin virologically suppressed patients. ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced detailed study results from its phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir and rilpivirine .

First-Grader Puts Personal Spin on Bell-Ringing to Signal End to Years of Chemotherapy

Videos posted by his mother, Lacie Spagnolo, to social media chronicling his fight against cancer show him bopping, smiling and clapping down hospital hallways. So it made sense that after Jimmy, a first-grader from right outside of Pittsburgh, rang a bell last week signaling the end of his final chemotherapy treatment, he screamed, hugged his family and then, of course, began dancing.

Will Seattle Genetics’ Deal With Immunomedics Get Scuttled?

The deal could be a big win for Seattle Genetics, but it doesn’t have the full support of all of Immunomedics investors. After the closing market bell on Friday, venBio Select Advisors, LLC — the beneficial owner of 9.9% of Immunomedics shares — said Immunomedics’ board of directors is “giving away its crown jewel.”

NHC Announces Common Dividend

)– National HealthCare Corporation (NYSE MKT: NHC), the nation’s oldest publicly traded long-term health care company, announced today that it will pay a quarterly dividend of 45 cents per common share to shareholders of record on March 31, 2017 and …

CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results

SCI reported the net income available to common shareholders for the quarter ended December 31, 2016 was $3,536,802 or $0.02 per basic share, versus $2,341,813 or $0.02 per basic share during the quarter ended December 31, 2015. CEL-SCI reported an operating loss of for the quarter ended December 31, 2016 versus an operating loss of for the quarter ended December 31, 2015.

Increasing Dental Tourism Boosts Demand for Orthodontic Equipment and Consumables Market

The heavily consolidated global orthodontics equipment and consumables market is dominated by Danaher Corporation, DENTSPLY International Inc., and Patterson Companies Inc. According to Transparency Market Research, these three leading players accounted for 63.5% of the orthodontic equipment and consumables market in 2013, with the next two companies collectively accounting for more than 20% of the market.

Merck profit soars on new drugs, expects better 2017

Merck CEO Kenneth Frazier on Thursday said he’s encouraged by an initial meeting he and other pharmaceutical executives had Tuesday with Trump, who has said drugmakers have been The pharmaceutical industry has come under fire in recent months over soaring drug prices, which have been blasted by patients, doctors, politicians and others. Drug companies and investors have been alternatively worried that the Trump administration and Congress will move to reduce prices, and cheered by hopes that they will help them increase profits by reducing taxes and reducing regulations so they can bring new drugs to market faster.

View Press Release

The Summit aims to showcase innovative organizations and how they are responding to changes occurring in the cancer care marketplace. “Today’s community oncology practices face many decisions and challenges, from new reimbursement structures to care models and technologies,” said Randy Hyun, senior vice president and general manager, Provider Solutions, McKesson Specialty Health.

Merck 2017 forecast eases concerns over royalty payments, dollar

Merck & Co Inc reported better-than-expected U.S. quarterly sales for its key cancer drug, Keytruda, and forecast largely in-line 2017 results, which some analysts said allayed concerns over the impact of a strong dollar and royalty payments. The logo of Merck is pictured in this illustration photograph in Cardiff, California April 26, 2016.

Global Auto-Injector Market is Expected to Grow at CAGR 18% and USD 2.9 Billion By 2022

Auto-Injector Device Market Expected To Grow At the CAGR of ~18%, Auto-Injector Market Size Is Expected To Increase by USD 2.9 Billion by the End of 2022 Key Players – SHL Group , Jiangsu Delfu medical device Co., Ltd , Becton, Dickinson and Company , Novartis International AG , Pfizer Inc., Ypsomed Holding AG , Unilife Corporation and Owen Mumford” PUNE, MAHARASTRA, INDIA, February 1, 2017 / EINPresswire.com / — Market Highlights Auto-Injector Market has been evaluated to be rapidly growing and expected to maintain this growth rate. Moreover, there is a huge possibility that the market will grow further in future.

Roche Sees Sales Boost in 2017 With New Lung Drug on U.S. Market

Roche Holding AG pointed toward rising sales this year as its new cancer immune therapy Tecentriq gains wider use for lung tumors. Revenue will probably rise by a low to mid-single digit percentage at constant exchange rates, the same pace as earnings per share excluding some items, the Basel, Switzerland-based company said in a statement Wednesday.

Pfizer Seeks Deals as Generic Versions Hurts Older Drugs’ Sales

Pfizer Inc. expects more generic competition for its established drugs in 2017, and the company’s deal-making to gain products may continue to thrive. After posting fourth-quarter earnings and a forecast that were short of analysts’ estimates, New York-based Pfizer said it would continue to pursue deals, regardless of their size, as long as they create shareholder value.

Dow 30 Earnings: Pfizer Fourth Quarter 2016

… quarter of 2015 had a negative impact of roughly $750 million. On the operating front, the company’s Innovative Health segment, which sells newer, patent-protected drugs, contributed sales of $7.7 billion (+1%), driven by continued growth of …

Aevi Genomic Medicine Announces Enrollment of First Patient in Phase…

“We are pleased to have the first patient enrolled into this important study,” said Garry Neil, Chief Scientific Officer of Aevi Genomic Medicine. “Patients with 22q Deletion Syndrome often suffer from a range of debilitating psychiatric conditions, including anxiety disorders, ASD, and ADHD, with many patients progressing to psychosis and schizophrenia.

What Will You Hear on Pfizer’s Fourth-Quarter Call Tuesday?

What’s likely to be at the top of investors’ minds during Pfizer’s fourth-quarter conference call Tuesday morning? How about Pfizer’s plans to overcome oncoming competition involving several important products while navigating what remains a difficult pricing environment? Clues from CEO Ian Read and the management team about the company’s capital deployment plans ought to be of high interest, too. In the wake of continued speculation around the sale of its consumer business, which operates as part of its Innovative Health segment and is home to the Chapstick and Advil brands, potential strategic M&A and divestitures could make up for slowing revenue growth seen across existing therapies.

European agency will review BioCryst’s flu drug

BioCryst Pharmaceuticals Inc., maker of the flu drug Rapivab, announced Monday that the European Medicines Agency will review its drug for the treatment of flu symptoms in adults. The London-based overseer of drugs sold in the European Union will issue a decision within 210 days on whether to allow the sale of Rapivab in the EU’s 28 member states and Norway and Iceland, a market of more than 500 million consumers.

BioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency

BioCryst Pharmaceuticals, Inc. , a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, announced today that the European Medicines Agency has accepted the filing of its peramivir Marketing Authorization Application for treatment of symptoms typical of influenza in adults 18 years and older. The acceptance of the MAA begins the review process by the EMA under the centralized licensing procedure for all 28 member states of the European Union, Norway and Iceland.

CytoDyn Strengthens Executive Management With Appointment of Anthony…

CytoDyn Inc. , a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus infection, announces the appointment of Anthony D. Caracciolo as Executive Chairman of CytoDyn effective immediately. In this new capacity, Mr. Caracciolo will assume an active leadership role in the Company’s strategic planning, business development and operations.

Flu Hospitalizations, Deaths Increasing: CDC

Although this year’s flu season appears to be an average one so far, more hospitalizations are being reported and deaths are increasing, federal health officials reported Friday. And it will be several weeks before the season peaks, said Lynnette Brammer, an epidemiologist with the U.S. Centers for Disease Control and Prevention.

Slim’s America Movil reports surprise 4th-qtr loss

Mexican telecoms company America Movil on Thursday said it swung to an almost 6 billion peso net loss in the fourth quarter. ), which is controlled by the family of billionaire Carlos Slim, said the 5.972 billion peso loss compared to a net profit of 15.663 billion pesos in the year-earlier quarter.

Trying to solve the Alzheimer’s puzzle

… of the 21st Century Cures Act, public funding for Alzheimer’s research has been rising. The National Institutes of Health allocated almost $1 billion to Alzheimer’s research in fiscal 2016 – a $350 million increase over the previous year, according …

Newer Hepatitis C Drugs May Pose Health Risks

Jan. 25, 2017 — Newer drugs to cure hepatitis C may put patients at risk for liver failure and other severe side effects, according to a new study from a U.S. nonprofit group that examines drug safety. The study by the Institute for Safe Medication Practices is based on an analysis of U.S. Food and Drug Administration data and reports from doctors worldwide on adverse events possibly caused by the nine widely used antiviral drugs, The New York Times reported.

Health Highlights: Jan. 25, 2017

Newer drugs to cure hepatitis C may put patients at risk for liver failure and other severe side effects, according to a new study from a U.S. nonprofit group that examines drug safety. The study by the Institute for Safe Medication Practices is based on an analysis of U.S. Food and Drug Administration data and reports from doctors worldwide on adverse events possibly caused by the nine widely used antiviral drugs, The New York Times reported.